<DOC>
	<DOCNO>NCT02857062</DOCNO>
	<brief_summary>The investigation evaluate , dermatological control , cutaneous in-use tolerance E45 Eczema Repair Emollient two three time daily application , period two week child baby dry/atopic dry/atopic skin .</brief_summary>
	<brief_title>To Evaluate Use Tolerance E45 Eczema Repair Emollient Babies Children With ( Very ( Dry/Atopic Skin</brief_title>
	<detailed_description>The investigation open label , in-use cutaneous tolerance investigation child baby dry/atopic dry/atopic skin , evaluate acceptability skin tolerability E45 Eczema Repair Emollient . The investigation 'at home ' user investigation test product apply parent/legal guardian pre-defined test site ( arm leg ) 2 3 time daily , consecutively 14 day .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Emollients</mesh_term>
	<criteria>1. female male 2. child age ≥3 year &lt; 12 year baby age ≥3 month &lt; 36 month screen 3. phototype I IV ( Fitzpatrick Phototyping Scale ) 4. skin dry/atopic dry/atopic ( confirmed Dermatologist consultation parent/legal guardian ) 5. mild atopic eczema ( confirmed Dermatologist consultation parent/legal guardian ) undergo steroid treatment condition 6. pigmentation select test site 7. general good health mental condition In addition parent/legal guardian must : 8 . Both parent case share custody/legal guardian provide write informed consent child/baby participate investigation ( child age 6 year , capable understanding investigation explain , ask provide assent . Preschoolers ( 25 year ) allow express level assent verbally relate ability ) 9. agree attend investigation centre , child/baby , predefined day 10. willing capable follow investigation requirement 1. chronic acute skin disease , except atopic eczema part body 2. active flare atopic eczema sit body screen 3. know allergy sensitivity cosmetic product and/or ingredient investigational product . 4. systemic illness would impact subject safety wellbeing and/or affect response skin interpretation test result screen ( Day 14 7 ) 5. receive follow topical systemic treatment baseline ( Day 0 ) ; antiinflammatory and/or antihistamine previous week cough suppressant and/or topical inhale corticosteroid previous 2 week retinoids and/or immunosuppressant previous 6 month 6. diabetes , acute cardiac circulatory disease , HIV , hepatitis 7. participation studies/investigations part body last 4 week 8. use dermatological therapeutic body within 7 day prior baseline ( Day 0 ) ( use product face , trunk , hand nappy area permit ) 9. swim within 48 hour prior baseline ( Day 0 ) 10. intensive/prolonged exposure sun within 30 day prior screen 11. plan change subject 's diet investigation ( e.g . wean ) 12. subject whose parent/legal guardian employee work manufacturer personal care product test facility 13. subject protective care 14. subject whose parent/legal guardian ( apply investigation product ) allergic investigation device ingredient 15 . Any clinically significant relevant abnormality medical history and/or condition medication would impact subject safety wellbeing and/or affect response skin interpretation test result opinion Principal Investigator designee</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>